AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Suesskind: Teva could gain 80% of Remeron market in 6 months.
(From Israel Business Arena)
Byline: Avishay Ovadia
Generic drug leader Teva (Nasdaq: TEVA; TASE:TEVA) received US Food and Drug Administration (FDA) approval to market generic Remeron on Friday. Sales of the ethical anti-depressant amount to $350 million a year.
Analysts estimate Teva's sales of generic Remeron will be $90-130 million a year, starting immediately.
Yesterday, Teva CFO Dan Suesskind said, "I believe we can achieve 80% market share within six months. The price [of generic Remeron] will be two-thirds of the ethical drug."
Teva will build its market share gradually, of course, which implies over $120 million in …
-
- Teva to Acquire Barr - Final.
-
News wire article from: Fair Disclosure Wire
July 18, 2008
700+ words
-
- Generic drug maker Teva's profit growth could reach 30%.
-
News wire article from: Asia Africa Intelligence Wire
February 13, 2003
700+ words
-
- Advantage Teva.
-
News wire article from: Asia Africa Intelligence Wire
July 14, 2003
700+ words
-
- Makov: 2004 is Teva's year.
-
News wire article from: Asia Africa Intelligence Wire
May 5, 2004
700+ words
-
- Event Brief of Teva to Acquire Barr - Final.
-
News wire article from: Fair Disclosure Wire
July 18, 2008
700+ words
